PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study.

Abstract Previous studies suggested that use of fenofibrate could significantly reduce the rate of progression into diabetic retinopathy (DR), and that retinal nerve fiber layer (RNFL) loss, which has been considered an important indicator for retinal neurodegeneration, might precede microvascular changes. The aim of this study was to assess the effect(s) of fenofibrate on RNFL thickness at early stage of DR in patients with type 2 diabetes mellitus (DM).
PMID
Related Publications

Effects of Diabetic Macular Edema on Repeatability of Retinal Nerve Fiber Layer Thickness Measurements at the Macular and Peripapillary Area Using Swept-Source Optical Coherence Tomography.

Retinal nerve fiber layer and ganglion cell complex thickness in patients with type 2 diabetes mellitus.

Neurodegeneration in Type 2 Diabetes: Evidence From Spectral-Domain Optical Coherence Tomography.

Correlation of retinal nerve fibre layer and macular thickness with serum uric acid among type 2 diabetes mellitus.

Correlation of optic retinal nerve fiber layer thickness and visual function in patients with nonproliferative diabetic retinopathy.

Authors

Mayor MeshTerms
Keywords

Diabetic retinopathy

Fenofibrate

Optical coherence tomography

Retinal nerve fiber layer

Journal Title bmc ophthalmology
Publication Year Start




PMID- 29669526
OWN - NLM
STAT- MEDLINE
DCOM- 20180430
LR  - 20180501
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Apr 18
TI  - The effect of fenofibrate on early retinal nerve fiber layer loss in type 2
      diabetic patients: a case-control study.
PG  - 100
LID - 10.1186/s12886-018-0769-3 [doi]
AB  - BACKGROUND: Previous studies suggested that use of fenofibrate could
      significantly reduce the rate of progression into diabetic retinopathy (DR), and 
      that retinal nerve fiber layer (RNFL) loss, which has been considered an
      important indicator for retinal neurodegeneration, might precede microvascular
      changes. The aim of this study was to assess the effect(s) of fenofibrate on RNFL
      thickness at early stage of DR in patients with type 2 diabetes mellitus (DM).
      METHODS: In this retrospective matched case-control study we included a cohort of
      89 patients with type 2 DM, aged 40 or above, between Jan 1, 2017 and March 31,
      2017. Among the subjects, 48 patients received fenofibrate therapy and the other 
      41 patients did not receive fenofibrate treatment. We defined use of fenofibrate 
      as the presence of any prescription for fenofibrate within 1 year before or any
      time after the diagnosis of DM, and all the patients had either no DR or
      non-proliferative diabetic retinopathy (NPDR). The fibrate users were well
      matched with non-fenofibrate users for gender, age and axial length. The RNFL
      thickness in all quadrants of both eyes was examined with spectral domain optical
      coherence tomography (SD-OCT). The multiple linear regression analysis was used
      to assess the association of RNFL thickness with potential risk factors of DR
      other than fenofibrate use. RESULTS: The non-fenofibrate users had significantly 
      reduced RNFL thickness of the superior quadrant of the right eye compared to the 
      fenofibrate users (t = 2.384, P = 0.019). On the contrary, BMI (p = 0.034) and
      ACR (p = 0.024) were both negatively correlated to the RNFL thickness of the
      right eye. CONCLUSION: Oral administration of fenofibrate was suggestively
      associated with thicker RNFL in superior quadrant of the right eye of patents
      with early DR.
FAU - Shi, Rui
AU  - Shi R
AD  - Department of Ophthalmology, Shaanxi Provincial People's Hospital, No.256 Youyi
      west Road, Xi'an, 710068, Shaanxi Province, China. [email protected]
FAU - Zhao, Lei
AU  - Zhao L
AD  - Department of Molecular Physiology and Biophysics, Holden Comprehensive Cancer
      Center, University of Iowa Carver College of Medicine, Iowa City, IA, 52242, USA.
FAU - Qi, Yun
AU  - Qi Y
AD  - Department of Ophthalmology, the First Affiliated Hospital of Xi'an Jiaotong
      University, Xi'an, 710061, Shaanxi Province, China.
LA  - eng
GR  - 2017SF-249/Science & Technology project for Social development of Shaanxi
      Province
PT  - Journal Article
DEP - 20180418
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Hypolipidemic Agents)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Retinopathy/*drug therapy/pathology
MH  - Female
MH  - Fenofibrate/*therapeutic use
MH  - Humans
MH  - Hypolipidemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nerve Fibers/*pathology
MH  - Regression Analysis
MH  - Retina/pathology
MH  - Retinal Ganglion Cells/*pathology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Tomography, Optical Coherence/methods
MH  - Visual Acuity
PMC - PMC5907214
OTO - NOTNLM
OT  - Diabetic retinopathy
OT  - Fenofibrate
OT  - Optical coherence tomography
OT  - Retinal nerve fiber layer
EDAT- 2018/04/20 06:00
MHDA- 2018/05/01 06:00
CRDT- 2018/04/20 06:00
PHST- 2017/10/21 00:00 [received]
PHST- 2018/04/06 00:00 [accepted]
PHST- 2018/04/20 06:00 [entrez]
PHST- 2018/04/20 06:00 [pubmed]
PHST- 2018/05/01 06:00 [medline]
AID - 10.1186/s12886-018-0769-3 [doi]
AID - 10.1186/s12886-018-0769-3 [pii]
PST - epublish
SO  - BMC Ophthalmol. 2018 Apr 18;18(1):100. doi: 10.1186/s12886-018-0769-3.